Search

A letter to the editor is presented in response to the article "Data Torturing," by J. L. Mills in the October 14, 1993 issue.

Human epidermal growth factor receptor 2 (HER2) status is used for decision-making in breast carcinoma treatment. The status is obtained through immunohistochemistry or in situ hybridization. These two methods have the disadvantage of necessitating tissue sampling, which is prone to error due to tumor heterogeneity or interobserver variability. Whole-body imaging might be a solution to map HER2 expression throughout the body. Methods: Twenty patients with locally advanced or metastatic breast carcinoma (5 HER2-positive and 15 HER2-negative patients) were included in this phase II trial to assess the repeatability of uptake quantification and the extended safety of the [ 68 Ga]Ga-NOTA-anti-HER2 single-domain antibody (sdAb). The tracer was injected, followed by a PET/CT scan at 90 min. Within 8 d, the procedure was repeated. Blood samples were taken for antidrug antibody (ADA) assessment and liquid biopsies. On available tissues, immunohistochemistry, in situ hybridization, and mass spectrometry were performed to determine the correlation of HER2 status with uptake values measured on PET. If relevant preexisting [ 18 F]FDG PET/CT images were available (performed as standard of care), a comparison was made. Results: With a repeatability coefficient of 21.8%, this imaging technique was repeatable. No clear correlation between PET/CT uptake values and pathology could be established, as even patients with low levels of HER2 expression showed moderate to high uptake. Comparison with [ 18 F]FDG PET/CT in 16 patients demonstrated that in 7 patients, [ 68 Ga]Ga-NOTA-anti-HER2 shows interlesional heterogeneity within the same patient, and [ 18 F]FDG uptake did not show the same heterogeneous uptake in all patients. In some patients, the extent of disease was clearer with the [ 68 Ga]Ga-NOTA-anti-HER2-sdAb. Sixteen adverse events were reported but all without a clear relationship to the tracer. Three patients with preexisting ADAs did not show adverse reactions. No new ADAs developed. Conclusion: [ 68 Ga]Ga-NOTA-anti-HER2-sdAb PET/CT imaging shows similar repeatability to [ 18 F]FDG. It is safe for clinical use. There is tracer uptake in cancer lesions, even in patients previously determined to be HER2-low or -negative. The tracer shows potential in the assessment of interlesional heterogeneity of HER2 expression. In a subset of patients, [ 68 Ga]Ga-NOTA-anti-HER2-sdAb uptake was seen in lesions with no or low [ 18 F]FDG uptake. These findings support further clinical development of [ 68 Ga]Ga-NOTA-anti-HER2-sdAb as a PET/CT tracer in breast cancer patients., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)

Competing Interests: The authors have no competing interests to declare.

We report the incidental diagnosis of acute asymptomatic appendicitis on a fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET/CT) performed for staging of a non small cell lung carcinoma. The patient was asymptomatic and laboratory tests were normal. The case illustrates: a) the possibility to diagnose appendicitis on (18)F-FDG PET/CT and b) the possibility of silent acute appendicitis, although this is a rare occurrence.

Objective: Granulomatosis with polyangiitis (GPA), formerly called Wegener's syndrome, is a vasculitis associated with antineutrophil cytoplasmic antibody and may occur in all ages but mostly in order adults. The organs most frequently involved are the ear, nose and throat (rhinitis, sinusitus, oral ulcers, chondritis), the lungs (nodules, sometimes cavitating, infiltrates, hilar adenopathy) and the kidneys (glomerulonephritis). As patients typically present with constitutional symptoms, the diagnosis can be challenging. We report the findings on position emission tomography/computed tomography (PET/CT) with fluorine-18-fluorodeoxyglucose ((18)F-FDG) in a patient with a limited form of GPA., Conclusion: None of the findings on PET are specific for GPA, but in a given clinical context, they may contribute to early diagnosis. They may guide biopsy taking, and may determine the extent of the disease. During and after treatment, PET can be used to monitor disease activity.

Objective: IgG4-related disease (IgG4-RD) is a systemic mass-forming fibro-inflammatory condition which can affect nearly every organ system. Its pathophysiology remains incompletely understood, but affected tissues are characterized by a lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells which cause chronic inflammation, storiform fibrosis and phlebitis. These findings on histopathological specimens are considered the gold standard for the diagnosis. Clinical signs and symptoms largely depend upon organ involvement which can be singular or multiple, synchronous or metachronous. The organs most frequently involved are the pancreas (autoimmune pancreatitis (AIP), salivary and lacrimal glands (Mickulicz disease and sclerosing sialadenitis), biliary tree (sclerosing cholangitis or cholecystitis), retroperitoneum (retroperitoneal fibrosis), aorta (periaortic fibrosis), kidneys (interstitial nephritis) and thyroid (Riedel thyroiditis). Presentation is mostly subacute and general symptoms such as weight loss, asthenia or fever are moderate, but more prevalent in multi-organ disease. Lesions often mimic malignancy, but most respond well to steroid therapy., Conclusion: In this contribution we present a rare entity of IgG4-RD and discuss the utility of fluorine-18-fluorodeoxyglucose ((18)F-FDG) Positron emission tomography/computed tomography (PET/CT) in the diagnosis and treatment of this condition.

Absolute quantification using single photon emission computed tomography (SPECT) was demonstrated in vitro and in large immobile organs in vivo. To determine the feasibility of in vivo quantification of myocardial perfusion in pinhole gated SPECT, we added an ultrasound derived partial volume correction factor to attenuation and scatter corrections, in combination with gated acquisitions. In nine male Wistar rats, cardiac ultrasound was performed prior to SPECT/CT scans to determine the myocardial wall thickness. SPECT/CT scans were then performed 30 min after injection of (99m) Tc Tetrofosmin. Animals were killed and six midventricular segments of the left ventricle were excised and counted in a γ-well counter. Using AMIDE, regional myocardial activity was measured after combined scatter correction (SC) and attenuation correction (AC). These image derived activities were compared with the ex vivo counted activity. To correct for the partial volume effect, a recovery coefficient was determined from a phantom study, to determine the thickness specific partial volume effect. Combined AC and SC led to a significant underestimation of activity compared with ex vivo data (root mean squared error = 0.145 mCi g(-1)). The recovery coefficient calculated from the phantom study showed a linear relationship with object size from 1 to 6 mm, positioned in the vicinity of the center of the field of view (R(2)  = 0.98). Correction of nongated SPECT images with a recovery coefficient derived from the diastolic phase results in a global overestimation with root mean squared error = 0.04 mCi g(-1). Nongated SPECT images corrected with a recovery coefficient with a weighted average ratio diastolic and systolic phase led to an improved root mean squared error of 0.03 mCi g(-1). Combining attenuation correction with scatter correction and a gated partial volume correction yields the best correlation with ex vivo counting (root mean squared error = 0.021 mCi g(-1) (systolic) and 0.025 mCi g(-1) (diastolic). This study demonstrates a method for improved segmental myocardial perfusion quantification in pinhole gated SPECT, using combined attenuation-, scatter- and ultrasound-derived partial volume effect corrections., (Copyright © 2012 John Wiley & Sons, Ltd.)

Background: (99m)Tc labeled radiotracers used in clinical practice lack the perfect characteristics for myocardial perfusion imaging. In particular, the high liver uptake can interfere in the interpretation of the inferior myocardial wall. Within the tricarbonyl approach, we used tris(pyrazolyl)methane (99m)Tc organometallic complexes as a lead structure. Herein we present the production, in vivo and in vitro metabolic studies in rats and the first in vivo biodistribution in rats for tri-methoxy-tris-pyrazolyl-(99m)Tc-(CO)(3) ((99m)Tc-TMEOP), compared with (99m)Tc-sestamibi and (99m)Tc-tetrofosmin., Methods: The chemical identity of (99m)Tc-TMEOP was characterized by RP-HPLC. The octanol-water partition coefficient was determined under physiological conditions. In vitro stability and protein binding were determined using RP-HPLC. In vivo stability was determined in blood, heart, liver and kidney homogenates, intestine and urine using RP-HPLC. In vivo biodistribution was determined using dynamic planar acquisitions. Pinhole gated SPECT images were performed in other animals. Cardiac, liver and lung uptake were expressed as differential uptake ratios by drawing regions of interest in the organs of interest and around the total body. Heart-liver and heart-lung ratios were derived. Cardiac uptake was also expressed as percentage of injected activity. SPECT images were processed to determine the heart-liver ratio on SPECT images, to compare functional parameters between different tracers and to visualize homogeneous intracardiac tracer distribution., Results: (99m)Tc-TMEOP is a moderately lipophilic cation, is stable and does not undergo any transformation in vitro. (99m)Tc-TMEOP also shows a high in vivo stability. In vivo imaging shows liver kinetics faster than those of (99m)Tc-sestamibi and (99m)Tc-tetrofosmin. Cardiac uptake and functional analysis of pinhole gated SPECT data are comparable to those of (99m)Tc-sestamibi and (99m)Tc-tetrofosmin., Conclusion: Although (99m)Tc-TMEOP shows a cardiac uptake between those of (99m)Tc-sestamibi and (99m)Tc-tetrofosmin, a better heart-liver ratio is obtained due to the faster liver washout. These results suggest possible faster cardiac perfusion imaging using (99m)Tc-TMEOP without liver activity interference., (Copyright © 2010 John Wiley & Sons, Ltd.)

Objective: The purpose of this study was to evaluate the diagnostic performance of digital tomosynthesis in comparison with digital radiography in the detection of urinary stones with MDCT as the reference standard., Subjects and Methods: Fifty consecutively enrolled patients (32 men, 18 women; mean age, 51.5 years; range, 19-83 years) referred for unenhanced MDCT of the abdomen with suspicion of urinary stones also underwent digital tomosynthesis and digital radiography (anteroposterior and bladder inlet views). Images from all examinations were randomly read by three blinded radiologists. The mean effective doses for digital tomosynthesis, digital radiography, and low- and high-dose MDCT were measured on a male phantom. Free-response receiver operating characteristics and receiver operating characteristics analyses were used to compare the diagnostic performance of digital radiography with that of digital tomosynthesis., Results: Both types of analysis showed significantly better performance of tomosynthesis over digital radiography for all urinary stones (p < 0.05). No such improvement was found for ureteral stones. The gain in sensitivity with tomosynthesis was largest for stones between 2 and 5 mm in diameter. The mean effective dose was 0.5 mSv for digital radiography, 0.85 mSv for tomosynthesis, 2.5 mSv for low-dose MDCT, and 12.6 mSv for high-dose MDCT., Conclusion: Use of digital tomosynthesis of the abdomen results in improved detection of urinary stones in general over digital radiography with only a slight increase in effective dose. Use of tomosynthesis, however, was not associated with major improvement in the diagnosis of ureteral stones. The technique has potential as an alternative imaging technique in the detection and follow-up of urinary stones.

Urinary bladder carcinoma sometimes can be recognized on bone scans as a filling defect in the bladder. This paper illustrates in three patients that the filling defects of urinary bladder on pelvic bone single photon emission tomography (SPET) scans in cases of bladder carcinoma correspond to those on computerized tomography (CT). In one patient, the void sign could only be discerned on the SPET images, but not on the planar images. In the same patient, the filling defect was almost entirely surrounded by urinary activity, suggesting an intrinsic bladder lesion. The differential diagnosis of filling defects is presented. The above findings are compared to other related studies, although we have found no similar cases in the literature. When compared with CT, pelvic SPET is more sensitive than planar imaging in recognizing bladder filling defects on bone scans and may allow distinguish between intrinsic and extrinsic bladder lesions.